Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Progenics Pharmaceuticals Announces Appointment of Bryce V. Tenbarge as Vice President of Commercial
NEW YORK, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating...
-
NEW YORK, Sept. 02, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating...
-
On July 19, the Company Announced FDA Approval of RELISTOR® Tablets, Triggering a $50 Million Milestone Ultra-Orphan Radiotherapeutic Candidate AZEDRA® Registrational Trial Topline Results...
-
TARRYTOWN, N.Y., July 26, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) announced today that it has received a $50 million milestone payment from its worldwide...
-
TARRYTOWN, N.Y., July 22, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating...
-
TARRYTOWN, N.Y., July 08, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating...
-
TARRYTOWN, N.Y., June 13, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) announced today that data from its 1404 and PyLTM prostate cancer imaging programs will be...
-
TARRYTOWN, N.Y., June 09, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating...
-
TARRYTOWN, N.Y., June 02, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company focused on developing innovative medicines and other products for targeting...
-
On May 2nd, the Company Announced It Had Granted Exclusive World-Wide Rights to Bayer to Develop and Commercialize Products Using Progenics’ PSMA Antibody Technology In Combination with Alpha-Emitting...